Research Article

Genetic Diversity of HIV-1 in Krasnoyarsk Krai: Area with High Levels of HIV-1 Recombination in Russia

Table 2

Characteristics of patients with HIV drug resistance mutations.

Code region of residenceAge (years)GenderTransmission risk groupHIV genotypeDrug resistance mutations (NRTI)Extent of ARVT (years NNRTI)The level of ARVT compliancePlasma HIV-1 RNA (copies/ml)††CD4+ cell count (cells/mm3)††

7Krasn.Krai40MPWIDA6M184VK103N5High598376
9Krasn. Krai33FNot availableA6A62V K65R V75I Y115FG190S2High8310343
40Krasnoyarsk36FHTsA6M184VK103N P225H10High1170598
61Krasnoyarsk58FHTsA6A62V K65R Y115FV179DY181C10Low227000032
73Norilsk46MHTsA6M184VG190S K101Q9High2703265
74Norilsk43MHTsA6A62V D67E T69S_SA L210W T215FK101E V179F Y181C Y188L V106I K238R6High390684
75Norilsk47MHTs with PWIDA6A62V K65R M184V10High13304183
77Norilsk35MPWIDURF63/AM184VK101E E138G G190S6Average2759654
79Norilsk36MPWIDURF02/AM184 T215FK101E G190S V90I V106I6Average379135
80Norilsk45MPWIDA6K103N7Average1490322
102Krasnoyarsk36FHTs with PWIDA6Y181C6Average703023
107Krasnoyarsk39FHTsA6K65RY181C G190S K101Q1High535000239
109Krasnoyarsk37MPWIDA6M184V T215FG190S K101Q7High52500293
110Krasn. Krai38FHTsA6A62V D67GE138K3Average49500473
131Krasnoyarsk45MPWIDURFA/BK65R, Y115DK103N Y181 V179I1Average146000123
149Krasnoyarsk39FHTsA6T215S5High1640296
150Krasnoyarsk38MPWIDA6M184VK103N P225H6Average4930307
583Norilsk39MPWIDA6D67N K70RA98G10High1750347
658Norilsk35MPWIDA6A62V K70E M184VK101E E138A G190S8Average342143120
3Krasnoyarsk36MHTsА6L74I M184V K219EA98GY 181C G190S6Average2600000121
16.2Krasn. Krai33FHTsА6M41L L74I V75IM M184V T215S Q151MK103N E138K G190S4High201000148

Gender: M: male; F: female. transmission risk group: PWID: people who inject drugs; HTs: people infected via heterosexual contacts. HIV-1 genotype: the result of HIV-1 genotyping obtained after analysis of the complex of data: phylogenetic analysis from RP-RT, IN, and env regions and additional recombination analysis in case of inconsistency of genotyping results. The level of ARVT compliance was determined after individual interview with epidemiologist; ††plasma HIV-1 RNA and CD4+ cell count detected at the time of sampling of clinical blood samples.